8 research outputs found
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
Background: Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity. The constitutively activated BCR/ABL-kinase "escapes" the auto-inhibition mechanisms of c-ABL, such as allosteric inhibition. The ABL-kinase inhibitors (AKIs) Imatinib, Nilotinib or Dasatinib, which target the ATP-binding site, are effective in Ph + leukemia. Another molecular therapy approach targeting BCR/ABL restores allosteric inhibition. Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia.
Methods: The efficacy of this approach on the leukemogenic potential of BCR/ABL was studied in Ba/F3 cells, primary murine bone marrow cells, and untransformed Rat-1 fibroblasts expressing BCR/ABL or BCR/ABL-T315I as well as in patient-derived long-term cultures (PDLTC) from Ph + ALL-patients.
Results: Here, we show that GNF-2 increased the effects of AKIs on unmutated BCR/ABL. Interestingly, the combination of Dasatinib and GNF-2 overcame resistance of BCR/ABL-T315I in all models used in a synergistic manner.
Conclusions: Our observations establish a new approach for the molecular targeting of BCR/ABL and its resistant mutants using a combination of AKIs and allosteric inhibitors
Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines
Chronic myeloid leukemia (CML) is characterized
by the presence of p210Bcr-Abl which exhibits an
abnormal kinase activity. Selective Abl kinase inhibitors
have been successfully established for the treatment of CML.
Despite high rates of clinical response, CML patients can
develop resistance against these kinase inhibitors mainly due
to point mutations within the Abl protein kinase domain.
Previously, we have identified oleic acid as the active component
in the mushroom Daedalea gibbosa that inhibited the
kinase activity of Bcr-Abl. Here, we report that the oleyl
amine derivatives, S-1-(1-Hydroxymethyl-2-methyl-propyl)-
3-octadec-9-enyl-urea [oleylaminocarbonyl-L-Nvalinol,
oroleylaminocarbonyl-S-2-isopropyl-N-ethanolamine,
oleylamine-carbonyl-L-valinol] (cpd 6) and R-1-(1-Hydroxymethyl-
2-methyl-propyl)-3-octadec-9-enyl-urea [oleylamineocarbonyl-
D-N-valinol, oleylaminocarbonyl-R-2-isopropyl-
N-ethanolamine, or oleylamine-carbonyl-D-valinol]
(cpd 7), inhibited the activity of the native and T315I
mutated Bcr-Abl. Furthermore, cpd 6 and 7 exhibited higher
activity towards the oncogenic Bcr-Abl in comparison to
native c-Abl in SupB15 Ph-positive ALL cell line.This work was supported, in part, by DFG-RU
728/3-2 to MR, YN and JM
Ectopic expression of snail and twist in Ph+ leukemia cells upregulates CD44 expression and alters their differentiation potential
Philadelphia chromosome-positive (Ph+) leukemia is characterized by reciprocal translocation between chromosomes 9 and 22. The resultant BCR/ABL fusion protein displays constitutive tyrosine kinase activity, leading to the induction of aberrant proliferation and neoplastic transformation. The bone marrow (BM) microenvironment is tumor-promoting, and contributes to disease recurrence in Ph+ leukemia. Activity in the BM microenvironment is mediated by several cellular compartments, extracellular matrix, various soluble factors including transforming growth factor beta 1 (TGF-β1), and the hypoxic conditions in the BM niche. TGF-β1 is released during bone remodeling and plays a role in maintaining leukemic stem cells, as well as being implicated in the epithelial-mesenchymal transition (EMT) process in most solid tumors. Although EMT is largely implicated in epithelial tumors, recent findings argue for an EMT-like process in leukemia as well. The surface receptor CD44 is involved in cell adhesion, cell migration, and homing of normal and malignant hematopoietic stem cells. Elevation of CD44 expression is considered a marker for a worse prognosis in most hematological malignancies. We explored the functions of Snail and Twist1 in Ph+ leukemia. We showed that ectopic expression of Snail and, to a lesser extent, Twist1, upregulates CD44 expression that is β-catenin-dependent. Moreover, the presence of Snail or Twist1 partially blocked phorbol 12-myristate 13-acetate-induced megakaryocyte differentiation, while that of Twist significantly altered imatinib-induced erythroid differentiation. Thus EMT modulators affected proliferation, CD44 gene expression and differentiation ability of Ph+ leukemia cells
Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
ABSTRACT: BACKGROUND: Philadelphia positive leukemias are characterized by the presence of Bcr-Abl fusion protein which exhibits an abnormal kinase activity. Selective Abl kinase inhibitors have been successfully established for the treatment of Ph (+) leukemias. Despite high rates of clinical response, Ph (+) patients can develop resistance against these kinase inhibitors mainly due to point mutations within the Abl protein. Of special interest is the 'gatekeeper' T315I mutation, which confers complete resistance to Abl kinase inhibitors. Recently, GNF-2, Abl allosteric kinase inhibitor, was demonstrated to possess cellular activity against Bcr-Abl transformed cells. Similarly to Abl kinase inhibitors (AKIs), GNF-2 failed to inhibit activity of mutated Bcr-Abl carrying the T315I mutation.
METHODS: Ba/F3 cells harboring native or T315I mutated Bcr-Abl constructs were treated with GNF-2 and AKIs. We monitored the effect of GNF-2 with AKIs on the proliferation and clonigenicity of the different Ba/F3 cells. In addition, we monitored the auto-phosphorylation activity of Bcr-Abl and JAK2 in cells treated with GNF-2 and AKIs.
RESULTS: In this study, we report a cooperation between AKIs and GNF-2 in inhibiting proliferation and clonigenicity of Ba/F3 cells carrying T315I mutated Bcr-Abl. Interestingly, cooperation was most evident between Dasatinib and GNF-2. Furthermore, we showed that GNF-2 was moderately active in inhibiting the activity of JAK2 kinase, and presence of AKIs augmented GNF-2 activity.
CONCLUSIONS: Our data illustrated the ability of allosteric inhibitors such as GNF-2 to cooperate with AKIs to overcome T315I mutation by Bcr-Abl-independent mechanisms, providing a possibility of enhancing AKIs efficacy and overcoming resistance in Ph+ leukemia cells
Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
Natural products as potential cancer therapy enhancers: A preclinical update
Cancer is a multifactorial disease that arises as a consequence of alterations in many physiological processes. Recently, hallmarks of cancer were suggested that include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis, along with two emerging hallmarks including reprogramming energy metabolism and escaping immune destruction. Treating multifactorial diseases, such as cancer with agents targeting a single target, might provide partial treatment and, in many cases, disappointing cure rates. Epidemiological studies have consistently shown that the regular consumption of fruits and vegetables is strongly associated with a reduced risk of developing chronic diseases, such as cardiovascular diseases and cancer. Since ancient times, plants, herbs, and other natural products have been used as healing agents. Moreover, the majority of the medicinal substances available today have their origin in natural compounds. Traditionally, pharmaceuticals are used to cure diseases, and nutrition and herbs are used to prevent disease and to provide an optimal balance of macro- and micro-nutrients needed for good health. We explored the combination of natural products, dietary nutrition, and cancer chemotherapeutics for improving the efficacy of cancer chemotherapeutics and negating side effects
The Shaggy Inc Cap Medicinal Mushroom, Coprinus comatus (O.F.Mull.: Fr.) Pers. (Agaricomycetideae) Substances Interfere with H2O2 Induction of the NF-ÎşB Pathway through Inhibition of IÎşBÎą Phosphorylation in MCF7 Breast Cancer Cells
A Small Molecule Inhibitor of Brutonâs Tyrosine Kinase Involved in BâCell Signaling
Protein
kinases are fundamental within almost all cellular signal
transduction networks. Among these, Brutonâs tyrosine kinase
(Btk), which belongs to the Tec family of proteins, plays an imperative
part in B-cell signaling. Owing to its role, Btk has been established
as an important therapeutic target for a vast range of disorders related
to B-cell development and function, such as the X-linked agammaglobulinemia,
various B-cell malignancies, inflammation, and autoimmune diseases.
Herein, using computer-based screening of a library of 20 million
small molecules, we identified a small molecule capable of directly
binding the Btk kinase domain. On the basis of this hit compound,
we conducted a focused structure-similarity search to explore the
effect of different chemical modifications on binding toward Btk.
This search identified the molecule <i>N</i>2,<i>N</i>6-bisÂ(2,3-dihydrobenzoÂ[<i>b</i>]Â[1,4]Âdioxin-6-yl)-9<i>H</i>-purine-2,6-diamine as a potent inhibitor of Btk. The latter
small molecule binds Btk with a dissociation constant of 250 nM and
inhibits Btk activity both in vitro and in-cell